Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies.
Vaccine
; 38(27): 4236-4245, 2020 06 02.
Article
de En
| MEDLINE
| ID: mdl-32389497
ABSTRACT
The long-term persistence of antibody responses following primary vaccination with quadrivalent conjugate vaccines targeting meningococcal serogroups A, C, W, and Y (MenACWY) and the duration of protection following a booster dose have not been fully elucidated, particularly in children who received primary dosing as toddlers. This review summarizes the findings of one phase 3 and three phase 2 open-label, randomized clinical studies that assessed the long-term antibody persistence of MenACWY conjugated to tetanus toxoid as a carrier protein (MenACWY-TT) in toddlers. Following primary vaccination, antibody responses persisted for approximately 2-3â¯years and then decreased up to 5â¯years after vaccination. Geometric mean titers remained elevated for all serogroups up to 5â¯years after primary vaccination. In children who received a booster dose of MenACWY-TT at 4-5â¯years after primary dosing as toddlers, antibody responses were documented in >99% of subjects across all serogroups, with minimal decreases in antibody persistence from 2-6â¯years after booster vaccination. The persistence of meningococcal serogroup C (MenC) antibody responses was similar between MenACWY-TT and MenC vaccine recipients after primary and booster dosing. Together, these findings indicate that antibody responses to primary MenACWY-TT vaccination persist for 2-3â¯years. Additionally, these findings indicate that in subjects who receive primary MenACWY-TT vaccination as toddlers, the antibody response to booster MenACWY-TT vaccination lasts for up to 6â¯years and suggest that immune memory is afforded at least into early adolescence, which is an age group at increased risk of invasive meningococcal disease.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Vaccins antiméningococciques
/
Infections à méningocoques
Type d'étude:
Clinical_trials
Limites:
Adolescent
/
Child, preschool
/
Humans
Langue:
En
Journal:
Vaccine
Année:
2020
Type de document:
Article
Pays d'affiliation:
Royaume-Uni